Cocaine continues to be one of the most commonly abused illicit drugs in the United States. Pre-clinical literature suggests that targeting glucagon-like peptide-1 receptors (GLP-1Rs) in the brain may represent a novel approach to treating cocaine use disorder. Specifically, GLP-1R agonists, which are FDA-approved for treating diabetes and obesity, have been shown to reduce voluntary drug taking and seeking in preclinical models of cocaine used disorder.
source https://www.sciencedaily.com/releases/2020/12/201207153927.htm
Tuesday, 8 December 2020
Related Posts
Machine learning speeds up simulations in material scienceResearch, development, and production of novel materials depend heavil… Read More
Language extinction triggers loss of unique medicinal knowledgeIndigenous peoples pass on their knowledge of medicinal plants orally.… Read More
Key to carbon-free cars? Look to the starsScientists uncover new clues to the origins of the universe - and land… Read More
Physicists achieve significant improvement in spotting neutrinos in a cosmic haystackTwo articles describe how ground-breaking image reconstruction and ana… Read More
Maori connections to Antarctica may go as far back as 7th century, new study showsIndigenous Maori people may have set eyes on Antarctic waters and perh… Read More
The iron jaws of the bristle wormBristle worms have remarkably stable jaws. They are made of a very unu… Read More
0 comments: